Ignite Creation Date:
2025-12-24 @ 2:27 PM
Ignite Modification Date:
2026-01-03 @ 10:22 PM
Study NCT ID:
NCT00094159
Status:
COMPLETED
Last Update Posted:
2007-05-10
First Post:
2004-10-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
Sponsor:
Sunesis Pharmaceuticals
Organization:
Study Overview
Official Title:
Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Pharmacokinetic Profiles of Weekly Intravenous Administrations of SNS-595 in Patients With Advanced Malignancies
Status:
COMPLETED
Status Verified Date:
2007-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether SNS-595 given intravenously weekly for 3 weeks is safe.
Detailed Description:
Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the blood) and determining the dose and dose schedule for the next phase of studies with SNS-595.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: